Natco Pharma has announced a major expansion of its South African operations, with plans to invest nearly ₹2,500 crore to strengthen its regional footprint and enter new geographies across the African continent. The investment package includes up to ₹1,400 crore for Natco Pharma South Africa Proprietary Ltd, the company’s wholly owned subsidiary, and a substantial increase in its stake in local drugmaker Adcock Ingram Holdings Proprietary Ltd.
As part of the plan, Natco will raise its shareholding in Adcock Ingram from 35.75 per cent to 49 per cent by acquiring 19,618,825 shares at 92.50 South African rand per share, translating into an outlay of about ₹1,069 crore at prevailing exchange rates, excluding transaction costs and related expenses. The transaction, which is subject to customary approvals and regulatory clearances in India and South Africa, is expected to be completed by the end of July 2026.
The company said the increased stake in Adcock Ingram and capital infusion into its South African arm are aimed at expanding its geographic footprint, leveraging Adcock’s established market presence and revenue base, and positioning Natco to tap growth opportunities in the wider African pharmaceutical market. By consolidating nearly half of Adcock Ingram’s profits and backing its local subsidiary with fresh capital, Natco expects the move to strengthen its international portfolio and support long-term growth beyond its home market in India.
